LHVS

CAS: 170111-28-1 货号: L655138 分子式: C28H37N3O5S 分子量: 527.68 PubChem CID: 23648296
有货
级别和纯度: 10mM in DMSO
储存条件
-80℃储存
运输条件
特低温运输
★
规格
库存
价格
数量
1ml
L655138-1ml
期货 Stock Image
¥3,367.90
请输入您要添加的产品数量

概述


LHVS is a potent, non-selective, irreversible, cell-permeable cysteine protease and cathepsin inhibitor. LHVS decreases actin ring formation. LHVS inhibits T. gondii invasion with an IC 50 of 10 μM

In Vitro

LHVS (5 μM, 2 h) results in a 50% reduction of actin ring formation in wild-type osteoclasts when compared with untreated osteoclasts. LHVS acts in a dose-dependent manner on osteoclasts and at 5 μM, LHVS inhibits cathepsins K, L, S, and B. LHVS (1-5 nM) can inhibit specifically cathepsin S in HOM2 cells, leaving other cysteine proteases functionally active. LHVS impairs tachyzoite attachment by blocking the release of at least two key invasion proteins, MIC2 and M2AP, from the micronemes. LHVS (50 μM) selectively impairs microneme protein secretion. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

LHVS (3-30 mg/kg, SC, once) shows anti-hyperalgesic effect in neuropathic rats. LHVS (30 nmol per rat, spinal delivery, daily) is antinociceptive in neuropathic rats. LHVS (1-50 nmol per rat, Intrathecal injection, daily) reverses established neuropathic mechanical hyperalgesia in 14-day neuropathic rats. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats (180-220 g)Dosage: 3-30 mg/kg Administration: SC, once Result: Produced a dose-dependent reversal of the mechanical hyperalgesia which lasted up to 3 h in neuropathic rats. In contrast, a single systemic administration of LHVS did not reverse mechanical allodynia in neuropathic rats. Animal Model: Male Wistar rats received a partial ligation of the left sciatic nerve (PNL)Dosage: 30 nmol per rat Administration: Spinal delivery, Daily Result: Failed to prevent the development of allodynia when continuous delivery from day 0 to day 7 post-PNL, but significantly reversed allodynia on day 7 post-PNL. In addition, the delivery of LHVS from day 7 to day 14 post-PNL significantly reversed established mechanical allodynia from day 8. Animal Model: Male Wistar rats received a partial ligation of the left sciatic nerve (PNL)Dosage: 1, 10 or 50 nmol per rat Administration: Intrathecal injection, Daily Result: Reduced established mechanical hyperalgesia. This effect was dose-dependent and remained significant until 3 h after administration of the highest dose.

IC50& Target:cathepsin S cathepsin K cathepsin L Cathepsin B

规格

规格或纯度
10mM in DMSO
英文名称
LHVS
生化机理
LHVS 是一种强效、非选择性、不可逆、细胞渗透性半胱氨酸蛋白酶和酪蛋白酶抑制剂。LHVS 可减少肌动蛋白环的形成。LHVS 可抑制淋球菌入侵,其 IC 50 为 10 μM。
储存条件
-80℃储存
运输条件
特低温运输
作用类型
抑制剂
名称和识别符
分子类型
小分子
Isomeric SMILES
CC(C)C[C@H](C(=O)N[C@H](CCC1=CC=CC=C1)/C=C/S(=O)(=O)C2=CC=CC=C2)NC(=O)N3CCOCC3
PubChem CID
分子量
527.68

高级数据

关联靶点(人)
CTSL Tclin 组织蛋白酶L1(Cathepsin L1) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
CTSS Tchem 组织蛋白酶S(Cathepsin S) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
CTSK Tchem 组织蛋白酶K(Cathepsin K) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
CTSB Tchem 组织蛋白酶B(Cathepsin B) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
质检证书(CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
技术文档和文章
溶液计算器

常见问题

本产品应如何储存?
请于?80 °C条件下保存。需超低温保存以维持规定的有效期。
本产品如何运输?
本产品采用干冰配冷袋冷冻运输。收货后请立即拆包,并按上述储存条件保存;处理干冰时请戴隔热手套并保持通风。
本产品的 CAS 号、分子式和分子量是多少?
本产品的 CAS 号为 170111-28-1,分子式为 C28H37N3O5S,分子量为 527.68 g/mol。
如何获取批次专用COA?
每个订单都会随附分析证书(COA),您也可以从账户订单历史中下载。如需订购前的COA,请联系您的客户代表,或使用PDP上的"申请COA"按钮——我们将提供代表性批次的COA。